No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer.
Epidemiological studies suggest that ovarian cancer is an endocrine-related tumour, and progesterone exposure specifically may decrease the risk of ovarian cancer. To assess whether the progesterone receptor (PR) exon 4 valine to leucine amino acid variant is associated with specific tumour characteristics or with overall risk of ovarian cancer, we examined 551 cases of epithelial ovarian cancer and 298 unaffected controls for the underlying G-->T nucleotide substitution polymorphism. Stratification of the ovarian cancer cases according to tumour behaviour (low malignant potential or invasive), histology, grade or stage failed to reveal any heterogeneity with respect to the genotype defined by the PR exon 4 polymorphism. Furthermore, the genotype distribution did not differ significantly between ovarian cancer cases and unaffected controls. Compared with the GG genotype, the age-adjusted odds ratio (95% confidence interval) for risk of ovarian cancer was 0.78 (0.57-1.08) for the GT genotype, and 1.39 (0.47-4.14) for the TT genotype. In conclusion, the PR exon 4 codon 660 leucine variant encoded by the T allele does not appear to be associated with ovarian tumour behaviour, histology, stage or grade. This variant is also not associated with an increased risk of ovarian cancer, and is unlikely to be associated with a large decrease in ovarian cancer risk, although we cannot rule out a moderate inverse association between the GT genotype and ovarian cancer.
Spurdle
A B
AB
Oncology Division, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Herston, Queensland, Australia. mandyS@qimr.edu.au
Webb
P M
PM
Purdie
D M
DM
Chen
X
X
Green
A
A
Chenevix-Trench
G
G
D001483:Base Sequence; D016022:Case-Control Studies; D017931:DNA Primers; D005091:Exons; D005260:Female; D018740:Genetic Heterogeneity; D006801:Humans; D007930:Leucine / Q000235:genetics*; D016017:Odds Ratio; D010051:Ovarian Neoplasms / Q000235:genetics*; D017354:Point Mutation; D011110:Polymorphism, Genetic; D011980:Receptors, Progesterone / Q000235:genetics*; D014633:Valine / Q000235:genetics*
D017931:DNA Primers; D011980:Receptors, Progesterone; D007930:Leucine; D014633:Valine